top of page

Oncology M&A Valuation Segment Report

Comparable Transactions / Precedent Deals

 

Excel spreadsheet with Scope Research's cancer center/oncology M&A valuation data. Transactions segmented by type, which includes radiation therapy, proton therapy, radiosurgery, and medical oncology practices and PPMs.

 

  • 35 transactions with revenue or EBITDA multiples
  • 28 of these deals have EBITDA Multiples
  • Last updated 6/1/2026

 

Each transaction includes price to revenue and/or EBITDA multiples. We provide the names of the parties, transaction date, ownership percentage acquired, deal price (stated on a total enterprise value basis), time period of the financial information relied upon, revenue and/or EBITDA, and a description of our source documents and key details related to the financial information presented. 

 

Reach out to will@scoperesearch.co for more information.


All transactions included in the Scope Research healthcare M&A valuation database are meticulously researched and sourced. Our internal records include an audit trail of links to the majority of our sources.

Oncology

$950.00Price
    bottom of page